Abstract: Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function.
Keywords: Parkinson’s disease; amantadine; motion; cognition
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Muhlack, S.; Müsch, P.; Konietzka, S.; Woitalla, D.; Przuntek, H.; Müller, T. Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics 2010, 2, 313-320.
Muhlack S, Müsch P, Konietzka S, Woitalla D, Przuntek H, Müller T. Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics. 2010; 2(3):313-320.
Muhlack, Siegfried; Müsch, Patricia; Konietzka, Sandra; Woitalla, Dirk; Przuntek, Horst; Müller, Thomas. 2010. "Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease." Pharmaceutics 2, no. 3: 313-320.